Company news

Arcus Biosciences, Inc. news in 2026

Arcus Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update

November 4, 2026

Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London

November 2, 2026

Arcus Biosciences Announces New Employment Inducement Grants

October 26, 2026

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

October 21, 2026

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

October 21, 2026

Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer

October 20, 2026

Arcus Biosciences Announces New Employment Inducement Grants

October 9, 2026

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

September 22, 2026

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

August 5, 2026

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients

July 22, 2026

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

July 22, 2026

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates

July 21, 2026

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD-L1/VEGF-A Bispecific Immunomodulator to Treat Kidney Cancer

June 4, 2026

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

June 3, 2026

Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

May 5, 2026

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates

April 21, 2026

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

February 25, 2026

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

February 23, 2026

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates

February 11, 2026

Arcus Biosciences Announces New Employment Inducement Grants

January 26, 2026

Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs

January 7, 2026

Calls in 2026

Decks in 2026